Crenolanib vs. MidostaurinStudy of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Sponsor:

Arog Pharmaceuticals, Inc.

Code:

NCT03258931

Conditions

Newly Diagnosed FLT3 Mutated AML

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Crenolanib

Midostaurin

Cytarabine

Duanorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-27. This information was provided to ClinicalTrials.gov by Arog Pharmaceuticals, Inc. on 2020-05-22.